Oncostatin M (OSM) protects against cardiac ischaemia/reperfusion injury in diabetic mice by regulating apoptosis, mitochondrial biogenesis and insulin sensitivity

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 6, 2015, Pages 1296-1307

  Sun, Dongdong ^a   Li, Shuang ^a   Wu, Hao ^b   Zhang, Mingming ^a   Zhang, Xiaotian ^a   Wei, Liping ^c   Qin, Xing ^a   Gao, Erhe ^d  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c TIANJIN UNION MEDICAL CENTER   (China)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes; Inositol pyrophosphate 7; Ischaemia Reperfusion injury; Oncostatin M

Indexed keywords

MUS;

GLUCOSE; INOSITOL PHOSPHATE; ONCOSTATIN M; ONCOSTATIN M RECEPTOR; PROTECTIVE AGENT;

129 MOUSE; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CARDIAC MUSCLE; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GENETICS; HOMEOSTASIS; INSULIN RESISTANCE; KNOCKOUT MOUSE; METABOLISM; MUTANT MOUSE STRAIN; MYOCARDIAL REPERFUSION INJURY; ORGANELLE BIOGENESIS; PATHOLOGY; PATHOPHYSIOLOGY; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE; HOMEOSTASIS; INOSITOL PHOSPHATES; INSULIN RESISTANCE; MICE, 129 STRAIN; MICE, KNOCKOUT; MICE, MUTANT STRAINS; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; ONCOSTATIN M; ORGANELLE BIOGENESIS; PROTECTIVE AGENTS; RECEPTORS, ONCOSTATIN M;

EID: 84929966581     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12501     Document Type: Article

References (31)

1. Donahoe SM, Stewart GC, McCabe CH, et al. Diabetes and mortality following acute coronary syndromes. JAMA. 2007; 298: 765-75.
2. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106: 3143-421.
3. Creager MA, Luscher TF, Cosentino F, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation. 2003; 108: 1527-32.
4. Cao F, Sun D, Li C, et al. Long-term myocardial functional improvement after autologous bone marrow mononuclear cells transplantation in patients with ST-segment elevation myocardial infarction: 4 years follow-up. Eur Heart J. 2009; 30: 1986-94.
5. Sun D, Narsinh K, Wang H, et al. Effect of autologous bone marrow mononuclear cells transplantation in diabetic patients with ST-segment elevation myocardial infarction. Int J Cardiol. 2013; 167: 537-47.
6. Rocha M, Apostolova N, Herance JR, et al. Perspectives and potential applications of mitochondria-targeted antioxidants in cardiometabolic diseases and type 2 diabetes. Med Res Rev. 2014; 34: 160-89.
7. Balaban RS. Perspectives on: SGP symposium on mitochondrial physiology and medicine: metabolic homeostasis of the heart. J Gen Physiol. 2012; 139: 407-14.
8. Montaigne D, Marechal X, Lefebvre P, et al. Mitochondrial dysfunction as an arrhythmogenic substrate: a translational proof-of-concept study in patients with metabolic syndrome developping post-operative atrial fibrillation. J Am Coll Cardiol. 2013; 62: 1466-73.
9. Victor VM, Rocha M, Herance R, et al. Oxidative stress and mitochondrial dysfunction in type 2 diabetes. Curr Pharm Des. 2011; 17: 3947-58.
10. Tanaka M, Miyajima A. Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol. 2003; 149: 39-52.
11. Rega G, Kaun C, Weiss TW, et al. Inflammatory cytokines interleukin-6 and oncostatin m induce plasminogen activator inhibitor-1 in human adipose tissue. Circulation. 2005; 111: 1938-45.
12. Hohensinner PJ, Kaun C, Rychli K, et al. The inflammatory mediator oncostatin M induces stromal derived factor-1 in human adult cardiac cells. FASEB J. 2009; 23: 774-82.
13. Weiss TW, Kvakan H, Kaun C, et al. The gp130 ligand oncostatin M regulates tissue inhibitor of metalloproteinases-1 through ERK1/2 and p38 in human adult cardiac myocytes and in human adult cardiac fibroblasts: a possible role for the gp130/gp130 ligand system in the modulation of extracellular matrix degradation in the human heart. J Mol Cell Cardiol. 2005; 39: 545-51.
14. Weiss TW, Speidl WS, Kaun C, et al. Glycoprotein 130 ligand oncostatin-M induces expression of vascular endothelial growth factor in human adult cardiac myocytes. Cardiovasc Res. 2003; 59: 628-38.
15. Kubin T, Poling J, Kostin S, et al. Oncostatin M is a major mediator of cardiomyocyte dedifferentiation and remodeling. Cell Stem Cell. 2011; 9: 420-32.
16. Chakraborty A, Koldobskiy MA, Bello NT, et al. Inositol pyrophosphates inhibit Akt signaling, thereby regulating insulin sensitivity and weight gain. Cell. 2010; 143: 897-910.
17. Zhang Y, Wei L, Sun D, et al. Tanshinone IIA pretreatment protects myocardium against ischaemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway in diabetic rats. Diab Obes Metab. 2010; 12: 316-22.
18. Zhang Z, Liang D, Gao X, et al. Selective inhibition of inositol hexakisphosphate kinases (IP6Ks) enhances mesenchymal stem cell engraftment and improves therapeutic efficacy for myocardial infarction. Basic Res Cardiol. 2014; 109: 417.
19. Sun D, Shen M, Li J, et al. Cardioprotective effects of tanshinone IIA pretreatment via kinin B2 receptor-Akt-GSK-3beta dependent pathway in experimental diabetic cardiomyopathy. Cardiovasc Diabetol. 2011; 10: 4.
20. Sun D, Huang J, Zhang Z, et al. Luteolin limits infarct size and improves cardiac function after myocardium ischemia/reperfusion injury in diabetic rats. PLoS ONE. 2012; 7: e33491.
21. Mellin V, Isabelle M, Oudot A, et al. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure. Eur Heart J. 2005; 26: 1544-50.
22. Vives-Bauza C, Starkov A, Garcia-Arumi E. Measurements of the antioxidant enzyme activities of superoxide dismutase, catalase, and glutathione peroxidase. Methods Cell Biol. 2007; 80: 379-93.
23. Song JQ, Teng X, Cai Y, et al. Activation of Akt/GSK-3beta signaling pathway is involved in intermedin(1-53) protection against myocardial apoptosis induced by ischemia/reperfusion. Apoptosis. 2009; 14: 1299-307.
24. Rondelet B, Dewachter C, Kerbaul F, et al. Prolonged overcirculation-induced pulmonary arterial hypertension as a cause of right ventricular failure. Eur Heart J. 2012; 33: 1017-26.
25. Padmalayam I. Targeting mitochondrial oxidative stress through lipoic acid synthase: a novel strategy to manage diabetic cardiovascular disease. Cardiovasc Hematol Agents Med Chem. 2012; 10: 223-33.
26. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000; 404: 787-90.
27. Victor VM, Rocha M, Banuls C, et al. Mitochondrial dysfunction and targeted drugs: a focus on diabetes. Curr Pharm Des. 2011; 17: 1986-2001.
28. Jager S, Handschin C, St-Pierre J, et al. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci USA. 2007; 104: 12017-22.
29. Patti ME, Butte AJ, Crunkhorn S, et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci USA. 2003; 100: 8466-71.
30. Stump CS, Short KR, Bigelow ML, et al. Effect of insulin on human skeletal muscle mitochondrial ATP production, protein synthesis, and mRNA transcripts. Proc Natl Acad Sci USA. 2003; 100: 7996-8001.
31. Stratford S, Hoehn KL, Liu F, et al. Regulation of insulin action by ceramide: dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. J Biol Chem. 2004; 279: 36608-15.